VRC5283 Zika Virus Vaccine

VRC5283 is a Zika Virus DNA Vaccine candidate composed of a single closed-circular DNA plasmid that encodes with wild-type precursor transmembrane M and envelope proteins from the H/PF/2013 strain of ZIKV.  The vaccine was developed by the Vaccine Research Center, NIAID. VRC5283 is a new vaccine candidate that instructs the body to make a small amount of Zika virus protein. The body may use this to build an immune response.

An overview of the continuing development of vaccines and monoclonal antibodies against the Zika virus was published on May 24, 2024.

VRC5283 Vaccine Dosage

The vaccine is supplied in single-dose vials at a concentration of 4 mg/mL. ZIKV DNA vaccine dose will be 4 mg administered as an intramuscular (IM) injection in the deltoid muscle.

VRC5283 Vaccine News

December 4, 2017 - Gene-based Zika vaccine is safe and immunogenic in healthy adults

VRC5283 Clinical Trials

VRC5283 has completed two clinical trials.